1 / 19

Amanda Rivera-Begeman; Carrye Cost;

Comparison of genetic, antigenic and clinical features of extra-osseous Ewing Sarcoma (EO-EWS) and osseous Ewing sarcoma (O-EWS). Amanda Rivera-Begeman; Carrye Cost; Stephen Lessnick; Richard Smith; Charles Timmons; Patrick Leavey Annual CTOS Meeting; Seattle, Washington, November 2007.

garrett-tucker
Download Presentation

Amanda Rivera-Begeman; Carrye Cost;

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Comparison of genetic, antigenic and clinical features of extra-osseous Ewing Sarcoma (EO-EWS) and osseous Ewing sarcoma (O-EWS) Amanda Rivera-Begeman; Carrye Cost; Stephen Lessnick; Richard Smith; Charles Timmons; Patrick Leavey Annual CTOS Meeting; Seattle, Washington, November 2007

  2. Background • Ewing's sarcoma family of tumors (EFT) • Osseous EWS (O-EWS), Extraosseous ES (EO-EWS), Peripheral primitive neuroectodermal tumor (pPNET) and Askin's tumor of chest wall (Carvajal,R. et al; Hematol Oncol Clin North Am 2005) • Cell surface protein MIC-2 (CD99) expressed on both O-EWS and EO-EWS (Ambros, IM; Cancer; 1991) • FLI-1 nuclear immunostain + ve in 70% of EWS and PNET cases (Folpe et al; Am J Surg Pathol; 2000)

  3. Background • EWS/FLI-1 is seen in patients with EFT (O’Sullivan,MJ et al; Hum Pathol; 2001) • Prior reports of treatment for EO-EWS demonstrated no advantage to the addition of Doxorubicin (Raney RB et al.; J Clin Oncol; 1997) • EO-EWS should be treated with strategies used for O-EWS vs. malignant mesenchymal tumors (Castex,M.P.; J Clin Oncol; 2007)

  4. Objective • To describe genetic, antigenic, and clinical features of patients with EO-EWS, primarily those of intra-abdominal origin • To compare genetic and antigenic features of EO-EWS to those of randomly chosen patients with O-EWS

  5. Patients • Eligibility criteria • EFT treated at Children’s Medical Center Dallas (1995 – 2005; n=52) • Availability of archival diagnostic material and clinical data

  6. Patients

  7. Methods • All immunostains were independently reviewed by 2 pathologists (CT, ARB) • Interpretation was subjective +ve vs. –ve • No grading was attempted

  8. Fli-1 weak positive Fli-1 strong positive

  9. CD99 (O13) Weak positive CD99 (O13) strong positive

  10. Results – positive staining

  11. Results – positive staining

  12. Cytokeratin Cam 5.2 positive Carcinoembryonic antigen (CEA) positive

  13. Results – positive staining

  14. Results – positive staining

  15. Results – positive staining

  16. Methods • RT-PCR • RNA extracted from formalin fixed, paraffin embedded tumor (Roche high pure RNA paraffin kit) • PCR was performed for EWS/FLI-1 • EWS/FLI-1 fusion type identified by melt curve analysis • EWS-FLI-1 fusion type confirmed by agarose gel electrophoresis • Alternate partners were examined as necessary (ews/fev, etv1, etv4 and erg)

  17. Results – EWS-FLI-1 type • Not type 1 or 2 • EO-EWS: confirmed t(11:22)(q24;q12) but no translocation products amplified • O-EWS: PCR product melting curve between types 1 and 2 but failed sequencing

  18. Summary • Negative FLI-1 nuclear staining does not exclude EWS-FLI-1 translocation positive EFT • While CEA +ve staining can be seen in EO-EWS it does not differentiate this from O-EWS • More type 2 fusions noted in patients with EO-EWS

  19. Conclusion • Variability may occur in immunostaining and genotype analysis of patients with extra-osseous Ewing sarcoma vs. osseous Ewing sarcoma.

More Related